ECSP16005679A - SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN - Google Patents

SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Info

Publication number
ECSP16005679A
ECSP16005679A ECIEPI20165679A ECPI201605679A ECSP16005679A EC SP16005679 A ECSP16005679 A EC SP16005679A EC IEPI20165679 A ECIEPI20165679 A EC IEPI20165679A EC PI201605679 A ECPI201605679 A EC PI201605679A EC SP16005679 A ECSP16005679 A EC SP16005679A
Authority
EC
Ecuador
Prior art keywords
paracetamol
celecoxib
inflammatory pain
treatment
synergistic combination
Prior art date
Application number
ECIEPI20165679A
Other languages
Spanish (es)
Inventor
Medellin Jorge Fernando Cantú
Original Assignee
More Pharma Corp S De R L De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16005679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corp S De R L De C V filed Critical More Pharma Corp S De R L De C V
Publication of ECSP16005679A publication Critical patent/ECSP16005679A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe y reclama una combinación de paracetamol y celecoxib que en cantidades específicas generan una potenciación analgésica contra el dolor de tipo inflamatorio. Específicamente, la invención se refiere una combinación sinergística de entre 375 a 500 mg de paracetamol y de entre 50 a 100 mg de celecoxib útil para el tratamiento de dolor inflamatorio en animales y seres humanos, así como el uso de dichos principios activos en las cantidades indicadas en la preparación de combinaciones farmacéuticas sinérgicas.A combination of paracetamol and celecoxib is described and claimed that in specific amounts generate an analgesic potentiation against inflammatory pain. Specifically, the invention refers to a synergistic combination of between 375 to 500 mg of paracetamol and between 50 to 100 mg of celecoxib useful for the treatment of inflammatory pain in animals and humans, as well as the use of said active principles in the amounts indicated in the preparation of synergistic pharmaceutical combinations.

ECIEPI20165679A 2013-07-11 2016-02-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN ECSP16005679A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/055710 WO2015004505A1 (en) 2013-07-11 2013-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain

Publications (1)

Publication Number Publication Date
ECSP16005679A true ECSP16005679A (en) 2017-08-31

Family

ID=52279400

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20165679A ECSP16005679A (en) 2013-07-11 2016-02-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Country Status (8)

Country Link
CL (1) CL2015003211A1 (en)
CR (1) CR20160021A (en)
CU (1) CU24440B1 (en)
DO (1) DOP2016000008A (en)
EC (1) ECSP16005679A (en)
MX (1) MX366118B (en)
PE (2) PE20170305A1 (en)
WO (2) WO2015004505A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package
PE20251233A1 (en) 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V MULTIACTIVE TABLET FOR THE TREATMENT AND CONTROL OF SEVERE CHRONIC PAIN AND PREPARATION METHOD
PE20251234A1 (en) * 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V CELECOXIB-ACETAMINOPHEN COMBINATION WITH ENHANCED STABILITY AND PROCEDURE FOR ITS PREPARATION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60325020D1 (en) * 2002-02-19 2009-01-15 Adcock Ingram Ltd PHARMACEUTICAL COMBINATIONS OF MELOXICAM, CODEIN PHOSPHATE AND PARACETAMOL
GB0423103D0 (en) * 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents

Also Published As

Publication number Publication date
WO2015004505A1 (en) 2015-01-15
PE20160239A1 (en) 2016-05-13
CU20160002A7 (en) 2016-06-29
PE20170305A1 (en) 2017-04-21
CR20160021A (en) 2016-04-08
WO2015004634A3 (en) 2015-04-09
CU24440B1 (en) 2019-09-04
MX366118B (en) 2019-06-27
WO2015004634A2 (en) 2015-01-15
CL2015003211A1 (en) 2016-04-29
MX2015013911A (en) 2015-12-08
DOP2016000008A (en) 2016-03-15

Similar Documents

Publication Publication Date Title
ECSP24031979A (en) THERAPEUTIC ACTIVE COMPOUNDS AND THEIR METHODS OF USE
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
CU20150163A7 (en) DERIVATIVES OF 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO (3,4-c) PIRAZOL-6-ONA ACTIVE AS BET INHIBITORS
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
CO6700827A2 (en) Corticosteroids for the treatment of joint pain
PE20180399A1 (en) TRANSDERMAL COMPOSITIONS OF IBUPROFEN AND METHODS OF USE OF THE SAME
MX2015009105A (en) COMPOSITIONS IN SOLID SOLUTION AND ITS USE IN CHRONIC INFLAMMATION.
CL2015002677A1 (en) Compositions comprising selenium and their use for the treatment and prevention of diseases or conditions associated with mitochondrial dysfunction.
CR20110596A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
CL2015002433A1 (en) Imidazopyridazines substituted
CL2019001996A1 (en) Therapeutic uses of an insect powder.
MX2016002892A (en) BINDING COMBINATIONS OF SIGMA AND NSAID RECEIVERS.
MX2015009045A (en) Compositions and methods for treating severe pain.
MX2018012285A (en) TREATMENT METHODS FOR COLESTIC AND FIBROTIC DISEASES.
MX367209B (en) AN INTRAVENOUS COMPOSITION INCLUDING IBUPROFEN AND PARACETAMOL IN COMBINATION.
CL2017000845A1 (en) Lysine Gingipain Inhibitors
NI201700078A (en) Pyrazolpyridinamines
BR112015029894A2 (en) solid pharmaceutical dosage form
BR112014031706A8 (en) Oral pharmaceutical compositions, and oral pharmaceutical composition comprising itraconazole
CL2016001130A1 (en) Solid triglyceride compositions and uses of these
ECSP16005679A (en) SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN
CL2012003119A1 (en) Pharmaceutical composition for injection that compensates for an aqueous solution of ibuprofen and trometamol, in which the concentration of ibuprofen is between 2 and 6 mg / ml, the concentration of trometamol is between 1.8 and 5.8 mg / ml, and the pH is between 7.0 and 9.5; and its use for the treatment of pain, inflammation or fever.
MX2016011025A (en) GRAPIPRANT COMPOSITIONS AND METHODS TO USE THE SAME.
CL2016000397A1 (en) Cancer treatment
MX376725B (en) Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals